Estelle Ayme-Dietrich

Dr. Estelle Ayme-Dietrich

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
LMLuc Maroteaux
Luc Maroteaux
EAEstelle Ayme-Dietrich
Estelle Ayme-Dietrich
GAGaëlle Aubertin-Kirch
Gaëlle Aubertin-Kirch
SBSophie Banas
Sophie Banas
EQEmily Quentin
Emily Quentin
LMLaurent Monassier
Laurent Monassier

8 January 2019 in Drugs
Verified
Journal Article
Closed access
PDF file
NCNicolas Collongues
Nicolas Collongues
EAEstelle Ayme-Dietrich
Estelle Ayme-Dietrich
LMLaurent Monassier
Laurent Monassier
JSJérôme de Seze
Jérôme de Seze

1 January 2017 in Archives of Cardiovascular Diseases
Verified
Journal Article
Closed access
EAEstelle Ayme-Dietrich
Estelle Ayme-Dietrich
GAGaëlle Aubertin-Kirch
Gaëlle Aubertin-Kirch
LMLuc Maroteaux
Luc Maroteaux
LMLaurent Monassier
Laurent Monassier

15 October 2017 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
EAEstelle Ayme-Dietrich
Estelle Ayme-Dietrich
RLRoland Lawson
Roland Lawson
FCFrancine Côté
Francine Côté
CTClaudia de Tapia
Claudia de Tapia
SSSylvia Da Silva
Sylvia Da Silva
LMLaurent Monassier
Laurent Monassier

1 February 2019 in Pharmacological Research
Verified
Journal Article
Closed access
EAEstelle Ayme-Dietrich
Estelle Ayme-Dietrich
RLRoland Lawson
Roland Lawson
SDSylvia Da-Silva
Sylvia Da-Silva
JMJean Philippe Mazzucotelli
Jean Philippe Mazzucotelli
LMLaurent Monassier
Laurent Monassier

1 November 2015 in Journal Of Hypertension
Verified
Journal Article
Closed access
EAEstelle Ayme-Dietrich
Estelle Ayme-Dietrich
HMHalim Marzak
Halim Marzak
RLRoland Lawson
Roland Lawson
WMWalid Mokni
Walid Mokni
OWOlivia Wendling
Olivia Wendling
LMLaurent Monassier
Laurent Monassier
Objective: Left-ventricular hypertrophy and interstitial fibrosis are the main pathophysiological factors of heart failure with preserved ejection fraction. Blockade of the serotonin 5-HT2B receptor (5-HT2BR) has been shown to reduce cardiac hypertrophy, oxidative stress, and extracellular cell matrix activation. In this study, we evaluated the effects of the 5-HT2BR blockade, on hemodynamic and cardiac remodeling, in spontaneously hypertensive rats (SHRs) that display a diastolic dysfunction with preserved ejection fraction. Method: Thirty-seven-week-old SHRs were randomized in four groups receiving either saline, the selective 5-HT2BR antagonist RS-127445 (1 mg/kg per day), a calcium channel blocker nicardipine (6 mg/kg per day), or RS-127445 + nicardipine. During the 14 weeks of treatment period, cardiac function and blood pressure were monitored by echocardiography and tail-cuff. Finally, electrocardiograms and invasive hemodynamics were obtained before blood collection. Heart was analyzed for morphology and mRNA expression. A complementary study evaluated the cardiac and vascular effects of serotonin on wild-type and mice knockout for the 5-HT2BR (Htr2B−/−) and/or the 5-HT2AR (Htr2A−/−). Results: Despite the left ventricular 5-HT2BR overexpression, 5-HT2BR blockade by RS-127445 did not affect left ventricular hypertrophy and fibrosis in SHRs. This antagonist did not improve diastolic dysfunction, neither alone nor in combination with nicardipine, although it induced plasma brain natriuretic peptide decrease. Moreover, RS-127445 amplified subendocardial fibrosis and favored left ventricular dilatation. Finally, a subendocardial left ventricular fibrosis was induced by chronic serotonin in wild-type mice, which was increased in Htr2B−/− animals, but prevented in Htr2A−/− and Htr2A/2B−/− mice, and could be explained by a contribution of the endothelial 5-HT2BRs to coronary vasodilatation. Conclusion: This work is the first to identify a cardioprotective function of the 5-HT2BR in an integrated model of diastolic dysfunction with preserved ejection fraction.